Hypertension and kidney disease progression

被引：11
作者：
Rigo, Diego [1 ]
Orias, Marcelo [1 ,2 ]
机构：
[1] Sanatorio Allende, Nephrol Dept, Cordoba, Argentina
[2] Univ Nacl Cordoba, Cordoba, Argentina
来源：
CLINICAL NEPHROLOGY | 2020年 / 93卷 / 07期
关键词：
hypertension; CKD; APOL1; nephrosclerosis; BLOOD-PRESSURE CONTROL; STAGE RENAL-DISEASE; RISK-FACTORS; NEPHROSCLEROSIS; VARIANTS;
D O I：
10.5414/CNP92S118
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
Hypertension is a common finding in patients with chronic kidney disease (CKD) and it is associated with kidney disease progression. Hypertensive nephropathy is a diagnosis, mostly based on clinical suspicion and defines many cases of CKD of unknown etiology. The risk of progression of hypertension-attributed nephropathy seems to have a genetic background as has been demonstrated in African-American patients with APOL1 gene risk variants.
引用
收藏
页码：S103 / S107
页数：5
相关论文
共 29 条
[1]   Structural and Functional Changes With the Aging Kidney [J].
Denic, Aleksandar ;
Glassock, Richard J. ;
Rule, Andrew D. .
ADVANCES IN CHRONIC KIDNEY DISEASE, 2016, 23 (01) :19-28
[2]   Accuracy of the diagnosis of hypertensive nephrosclerosis in African Americans: A report from the African American Study of Kidney Disease (AASK) Trial [J].
Fogo, A ;
Breyer, JA ;
Smith, MC ;
Cleveland, WH ;
Agodoa, L ;
Kirk, KA ;
Glassock, R ;
Faulkner, M ;
Kopple, JD ;
Massry, SG ;
Grim, C ;
Randall, OS ;
Toto, RD ;
Whelton, P ;
Wright, JT .
KIDNEY INTERNATIONAL, 1997, 51 (01) :244-252
[3]   Hypertension-attributed nephropathy: what's in a name? [J].
Freedman, Barry I. ;
Cohen, Arthur H. .
NATURE REVIEWS NEPHROLOGY, 2016, 12 (01) :27-36
[4]   Hypertensive nephrosclerosis [J].
Hill, Gary S. .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2008, 17 (03) :266-270
[5]   Epidemiology of Hypertension in CKD [J].
Horowitz, Bruce ;
Miskulin, Dana ;
Zager, Philip .
ADVANCES IN CHRONIC KIDNEY DISEASE, 2015, 22 (02) :88-95
[6]   Risk Factors for End-Stage Renal Disease 25-Year Follow-up [J].
Hsu, Chi-yuan ;
Iribarren, Carlos ;
McCulloch, Charles E. ;
Darbinian, Jeanne ;
Go, Alan S. .
ARCHIVES OF INTERNAL MEDICINE, 2009, 169 (04) :342-350
[7]   Does treatment of non-malignant hypertension reduce the incidence of renal dysfunction? A meta-analysis of 10 randomised, controlled trials [J].
Hsu, CY .
JOURNAL OF HUMAN HYPERTENSION, 2001, 15 (02) :99-106
[8]   Progression of chronic kidney disease: The role of blood pressure control, proteinuria, and angiotensin-converting enzyme inhibition - A patient-level meta-analysis [J].
Jafar, TH ;
Stark, PC ;
Schmid, CH ;
Landa, M ;
Maschio, G ;
de Jong, PE ;
de Zeeuw, D ;
Shahinfar, S ;
Toto, R ;
Levey, AS .
ANNALS OF INTERNAL MEDICINE, 2003, 139 (04) :244-252
[9]   Rethinking hypertensive kidney disease: arterionephrosclerosis as a genetic, metabolic, and inflammatory disorder [J].
Kopp, Jeffrey B. .
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2013, 22 (03) :266-272
[10]   Evaluation of cardiovascular disease burden and therapeutic goal attainment in US adults with chronic kidney disease: an analysis of national health and nutritional examination survey data, 2001-2010 [J].
Kuznik, Andreas ;
Mardekian, Jack ;
Tarasenko, Lisa .
BMC NEPHROLOGY, 2013, 14
123